Cost-effectiveness of tenofovir gel in urban South Africa: Model projections of HIV impact and threshold product prices

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Terris Prestholt, Fern ^a   Foss, Anna M ^a   Cox, Andrew P ^a   Heise, Lori ^a   Meyer Rath, Gesine ^a,b,c   Delany Moretlwe, Sinead ^d   Mertenskoetter, Thomas ^e   Rees, Helen ^d   Vickerman, Peter ^a   Watts, Charlotte H ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^e INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

ARV based prevention; Cost effectiveness; Economic analysis; HIV; Introduction of new technologies; Microbicides; Modelling; Pre exposure prophylaxis (PreP); South Africa; Tenofovir

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; MICROBICIDE; TENOFOVIR; ADENINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PHOSPHONIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; CIRCUMCISION; CONDOM USE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; DISABILITY; DRUG COST; ECONOMIC ASPECT; FEMALE; GENITAL ULCER; HEALTH CARE COST; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PREVALENCE; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SEXUAL INTERCOURSE; SOUTH AFRICA; URBAN POPULATION; VIRUS INFECTIVITY; VIRUS TRANSMISSION; ANALOGS AND DERIVATIVES; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; FORECASTING; HERPES GENITALIS; HIV INFECTIONS; STATISTICAL MODEL;

ADENINE; ANTI-HIV AGENTS; CIRCUMCISION, MALE; COST-BENEFIT ANALYSIS; FEMALE; FORECASTING; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; INCIDENCE; MALE; MODELS, ECONOMIC; ORGANOPHOSPHONATES; PREVALENCE; SOUTH AFRICA;

EID: 84892188124     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-14     Document Type: Article

References (57)

1. Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011, 365:493-505. 10.1056/NEJMoa1105243, 3200068, 21767103.
2. Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363:2587-2599. 10.1056/NEJMoa1011205, 3079639, 21091279.
3. Baeten J, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012, 367:399-410. 10.1056/NEJMoa1108524, 3770474, 22784037.
4. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, Henderson FL, Pathak SR, Soud FA, Chillag KL, et al. Antiretroviral Preexposure Prophylaxis for Heterosexual HIV Transmission in Botswana. N Engl J Med 2012, 367:423-434. 10.1056/NEJMoa1110711, 22784038.
5. Karim QA, Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, et al. Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in Women. Science 2010, Epub:http://www.sciencemag.org/content/early/2010/07/19/science.1193748? explicitversion=true.
6. Karim SSA. Results of the CAPRISA 004 trial of tenofovir gel. XVIII International AIDS Conference 18-23 July 2010, Vienna, Austria.
7. Cates W. After CAPRISA 004: time to re-evaluate the HIV lexicon. Lancet 2010, 376:495-496. 10.1016/S0140-6736(10)61200-7, 20709216.
8. FACTS 001 Study http://www.facts-consortium.co.za/?page_id=83.
9. Marrazzo J, Ramjee G, Nair G, Palanee T, Mkhize B, Nakabiito C, Taljaard M, Piper J, Gomez-Feliciano K, Chirenje M, VOICE Study Team Pre-exposure Prophylaxis for HIV in Women: Daily Oral Tenofovir, Oral Tenofovir/Emtricitabine, or Vaginal Tenofovir Gel in the VOICE Study (MTN 003). 20th Conference on Retroviruses and Opportunistic Infections; March 3-6 2013, Atlanta, Georgia, USA, VOICE Study Team.
10. Bärnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A 2012, 109:21271-21276. 10.1073/pnas.1209017110, 3535659, 23223563.
11. Shisana O, Rehle T, Simbayi L, Zuma K, Jooste S, Pillay-van-Wyk V, Mbelle N, Van Zyl J, Parker W, Zungu N, et al. South African national HIV prevalence, incidence, behaviour and communication survey. A turning tide among teenagers? 2009, Cape Town: HSRC Press.
12. Shisana O, Rehle T, Simbayi L, Parker W, Zuma K, Bhana A, Connolly C, Jooste S, Pillay V. South African National HIV Prevalence 2005, Behaviour and Communication Survey: HIV Incidence.
13. Dunkle K, Beksinka M, Rees H, Ballard R, Htun Y, Wilson ML. Risk factors for HIV infection among sex workers in Johannesburg, South Africa. Int J STD AIDS 2005, 16:256-261. 10.1258/0956462053420220, 15829029.
14. RHRU Reproductive Health Research Unit Behavioural Sentinel Survey Data Report - Clients of family planning - Gauteng 2000, Johannesburg, South Africa: Reproductive Health Research Unit, University of the Witwatersrand, RHRU.
15. Watts C, Foss A, Kumaranayake L, Cox A, Terris-Prestholt F, Vickerman P. Identifying optimal strategies for microbicide distribution in India and South Africa: Modelling and cost-effectiveness analyses. International Partnership for Microbicides with the London School of Hygiene and Tropical Medicine 2008, Brussels and London.
16. Rees H. Service Delivery and Demand Challenges in Introducing new health products 2008, Mexico City: Microbicide Access Forum.
17. Department of Health Medical Research Council, OrcMacro South Africa Demographic and Health Survey 2003 2007, Pretoria: Department of Health Republic of South Africa, Department of Health Medical Research Council, OrcMacro.
18. Heise L, Watts C, Foss A, Vickerman P, Trussell J, Hayes R, McCormack S. Apples and oranges? Interpreting success in HIV prevention trials. Contraception 2011, 83:10-15. 10.1016/j.contraception.2010.06.009, 3775591,3775591, 21134498.
19. Vickerman P, Foss A, Watts C. Using modeling to explore the degree to which a microbicide's sexually transmitted infection efficacy may contribute to the HIV effectiveness measured in phase 3 microbicide trials. J Acquir Immune Defic Syndr 2008, 48:460-467. 10.1097/QAI.0b013e31817aebd6, 18614928.
20. Vickerman P, Watts C, Delany S, Alary M, Rees H, Heise L. The importance of context: model projections on how microbicide impact could be affected by the underlying epidemiologic and behavioral situation in 2 African settings. Sex Transm Dis 2006, 33:397-405. 10.1097/01.olq.0000218974.77208.cc, 16721331.
21. Vickerman P, Foss AM, Pickles M, Deering K, Verma S, Demers E, Moses S, Alary M, Boily M-C. Is the Indian HIV epidemic driven by commercial sex? A modelling analysis from south India. AIDS 2010, 24:2563-2572. 10.1097/QAD.0b013e32833e8663, 20852405.
22. Garnett GP, Anderson RM. Strategies for limiting the spread of HIV in developing countries: conclusions based on studies of the transmission dynamics of the virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 9:500-513.
23. Weinstein MC, Graham JD, Siegel JE, Fineberg HV. Cost-effectiveness analysis of AIDS prevention programs: concepts, complications and illustrations. Confronting AIDS 1989, 471-499. Washington DC: National Academy Press, Turner CF, Miller HG, Moses LE.
24. Foss AM, Vickerman PT, Mayaud P, Weiss H, Ramesh BM, Reza-Paul S, Washington R, Blanchard J, Moses S, Lowndes CM, et al. Modelling the interactions between HSV-2 and HIV: implications for the HIV epidemic in southern India. Sex Transm Infect 2011, 87:22-27. 10.1136/sti.2009.041699, 21059838.
25. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, Kiwanuka N, Kigozi G, Kiddugavu M, Lutalo T, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005, 191:1403-1409. 10.1086/429411, 15809897.
26. Shisana O, Simbayi L. Nelson Mandela/HSRC study of HIV/AIDS. South African National HIV Prevalence, Behavioural Risks and Mass Media 2002, The Human Sciences Research Council: Cape Town.
27. Johnson LF, Coetzee DJ, Dorrington RE. Sentinel surveillance of sexually transmitted infections in South Africa: a review. Sex Transm Infect 2005, 81:287-293. 10.1136/sti.2004.013904, 1745020, 16061532.
28. CHOosing Interventions that are Cost Effective (WHO-CHOICE) [http://www.who.int/choice/costs/CER_thresholds/en/].
29. Bassett IV, Giddy J, Nkera J, Wang B, Losina E, Lu Z, Freedberg KA, Walensky RP. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr 2007, 46:181-186. 10.1097/QAI.0b013e31814277c8, 2140230, 17667332.
30. Terris-Prestholt F, Kumaranayake L, Obasi AI, Cleophas-Mazige B, Makokha M, Todd J, Ross DA, Hayes RJ. From Trial Intervention to Scale-Up: Costs of An Adolescent Sexual Health Program in Mwanza, Tanzania. Sex Transm Dis 2006, 33:S133-139. 10.1097/01.olq.0000200606.98181.42, 16652070.
31. Terris-Prestholt F, Michaels C, Kumaranayake L, Meyer-Rath G, Watts C. Costing Microbicide Distribution: Estimating cost-effectiveness & modelling potential role out 2009, Entebbe, Uganda: MDP301 Annual Investigators Meeting.
32. Meyer-Rath G. Public Sector Salary Costs. 2009, Personal Communicatuion.
33. Cleary S, Bouille A, McIntyre D, et al. Cost-effectiveness of Antiretroviral Treatment for HIV-positive Adults in a South African Township 2004, Cape Town: University of Cape Town, Health Systems Trust, Medecins Sans Frontieres.
34. Gilson L, Mkanje R, Grosskurth H, Mosha F, Picard J, Gavyole A, Todd J, Mayaud P, Swai R, Fransen L, et al. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania. Lancet 1997, 350:1805-1809. 10.1016/S0140-6736(97)08222-6, 9428251.
35. Bollinger L, Stover J, Boulle A, Cleary S. Database of Unit Costs for HIV and AIDS interventions in South Africa: Resource Needs for HIV/AIDS: Model for estimating resources needed for prevention, care and mitigation. Book Database of Unit Costs for HIV and AIDS interventions in South Africa: Resource Needs for HIV/AIDS: Model for estimating resources needed for prevention, care and mitigation 2006, City: Centre for Economic Governance and AIDS in Africa.
36. Friend D. Tenofovir 1% gel, Current Prices and Expected Prices at Different Scales. 2012, Personal communication.
37. Johnson L. Access to antiretroviral treatment in South Africa, 2004-2011. S Afr J HIV Med 2012, march:22-27.
38. Meyer-Rath G. National ART Cost Model, South Africa 2011, Johannesburg: Health Economics and Epidemiology Research Office, Boston University/University of the Witwatersrand.
39. Johansson KA, Robberstad B, Norheim OF. Further Benefits by Early Start of HIV Treatment in Low Income Countries: Survival Estimates of Early Versus Deferred Antiretroviral Therapy. AIDS Res Ther 2010, 7:3. doi:10.1186/1742-6405-7-3, 10.1186/1742-6405-7-3, 2836271, 20180966.
40. Fox-Rushby JA, Hanson K. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 2001, 16:326-331. 10.1093/heapol/16.3.326, 11527874.
41. Ortblad KF, Lozano R, Murray CJ. The burden of HIV: insights from the GBD 2010. AIDS (London, England) 2013,
42. GDP per capits (current US$) http://data.worldbank.org/indicator/NY.GDP.PCAP.CD.
43. Kashuba AD, Abdool Karim SS, Kraft E, White N, Sibeko S, Werner L, Mansoor LE, Gengiah T, Sidhoo S, Abdool Karim Q. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial?. XVIII International AIDS Conference 18-23 July 2010, Vienna, Austria.
44. Watts CH, Kumaranayake L, Vickerman P, Terris-Prestholt F. The public health impact of microbicides: model projections. Report from the Public Health Benefits Working Group. The Rockefeller Foundation Microbicide Initiative 2002, http://www.global-campaign.org/clientfiles/rep7_publichealth.pdf.
45. Watts C, Vickerman P. The impact of microbicides on HIV and STD transmission: model projections. AIDS 2000, 15:S43-S44.
46. Vickerman P, Devine A, Foss AM, Delany-Moretlwe S, Mayaud P, Meyer-Rath G. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis 2011, 38:401-409. 10.1097/OLQ.0b013e31820b8bc8, 21317689.
47. Terris-Prestholt F, Kumaranayake L, MacPhail C, Rees H, Watts C. Determinants of South African Women's Demand for New Barrier Methods and their Distribution: Analysis of a Discrete Choice Experiment. IAEN; 1-2 August; Cuernavaca 2008,
48. Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned?. AIDS 2003, 17:1227-1237. 10.1097/00002030-200305230-00015, 12819525.
49. Williams BG, Karim SSA, Karim QA, Gouws E. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa. J Acquir Immune Defic Syndr 2011, 58:207-210. 10.1097/QAI.0b013e3182253c19, 3175282, 21654503.
50. Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012, 54:1504-1513. 10.1093/cid/cis225, 3334365, 22474224.
51. Verguet S, Walsh JA. Vaginal microbicides save money: a model of cost-effectiveness in South Africa and the USA. Sex Transm Infect 2010, 86:212-216. 10.1136/sti.2009.037176, 20522634.
52. MDP Statement on the Discontinuation of Tenofovir gel in the VOICE Trial http://www.mdp.mrc.ac.uk/.
53. Gray RH, Li X, Kigozi G, Serwadda D, Nalugoda F, Watya S, Reynolds SJ, Wawer M. The impact of male circumcision on HIV incidence and cost per infection prevented: a stochastic simulation model from Rakai, Uganda. AIDS 2007, 21:845-850. 10.1097/QAD.0b013e3280187544, 17415039.
54. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One 2008, 3:e2212. 10.1371/journal.pone.0002212, 2387228, 18493593.
55. White RG, Glynn JR, Orroth KK, Freeman EE, Bakker R, Weiss HA, Kumaranayake L, Habbema JD, Buve A, Hayes RJ. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when?. AIDS 2008, 22:1841-1850. 10.1097/QAD.0b013e32830e0137, 18753931.
56. Cox AP, Foss AM, Vickerman PT, Chimbwete C, Okonji E, Terris-Prestholt F, Beksinska M, Walaza S, von Mollendorf C, Smit J, et al. Making realistic impact projections for new HIV prevention technologies: looking beyond a product's efficacy. 18th International Society for Sexually Transmitted Diseases Research; 28 June - 1 July 2009, London, UK.
57. Central Bank Rates http://www.cbrates.com.